Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Inclusion Criteria: * Written informed consent for the prospective cohort * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval. * High-risk sarcoma definition: * Greater than 5cm or Grade 3 * Deep anatomic location * Have disease amenable to biopsy o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study * Resectable tumour * Measurable disease by RECIST 1.1 * Aged ≥ 18 years * WHO performance status 0-2 * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy * Patients medically fit enough to undergo surgical resection * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule * Patients may also participate in the STRASS 2 trial Exclusion Criteria: -Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI. * Known additional malignancy that is progressing or requires active treatment * Metastatic disease not amenable to curative intent local therapy * Any active uncontrolled medical conditions